Increased serum or urinary concentrations of neopterin have been described in patients with tumors of different primary locations, but reports on neopterin in patients with melanoma are scanty. We have studied serum neopterin and a melanoma marker, S-100-beta, in 41 patients with melanoma. Serum neopterin and S-100-beta were determined by immunoassay. Neopterin concentrations were significantly increased compared to controls only in patients with active disease, but not in patients without evidence of disease activity. Serum neopterin and S-100-beta in patients with active disease were higher than in patients without evidence of disease activity. In patients a significant correlation existed between neopterin and S-100-beta (r s = 0.33, p <0.05), and, in patients without active disease, there was also a correlation between neopterin and age (r s = 0.51, p <0.01). In conclusion, increased serum neopterin in patients reflects disease activity. A significant correlation was observed between serum neopterin and S-100-beta. Future studies are necessary to demonstrate whether the combined measurement of serum neopterin and S-100-beta could be useful in the detection of recurrence in patients with melanoma.
Introduction
Malignant melanoma is the leading cause of mortality for skin cancer. The incidence of malignant melanoma has increased dramatically during the course of the 20th century. Surgery is the mainstay of curative treatment of malignant melanoma and is effective in patients with localized disease. However, a significant proportion of patients with initially localized tumors present with distant metastases during the course of follow up. Metastatic melanoma is usually amenable only to systemic therapy. Melanoma is, in general, resistant to cytotoxic agents. Dacarbazine, the most effective cytotoxic agent, induces objective response only in 10 -20 % of patients (1, 2) . Combination chemotherapy may result in higher response rate without any obvious effect on patient survival (3, 4) . Because of poor responsiveness to chemotherapy, biological agents have been used in therapy of malignant melanoma. Interleukin-2 and interferon-alpha are two most widely used biologicals in this tumor, but the effectiveness of therapy with these cytokines remains moderate (5, 6) . New active agents are needed for the therapy of malignant melanoma. Promising results have been reported for ipilimumab, monoclonal antibody against CD152 (7) . Similarly to interleukin-2 and, possibly, interferon-alpha, ipilimumab is effective through activation of the immune system of the host.
The activation of the immune system of the patient may be assessed by measuring serum or plasma cytokine concentrations. A significant problem associated with this approach is represented by fluctuations of systemic cytokine concentrations. Neopterin is a pteridine produced from guanosine triphosphate (GTP) by activated macrophages in a reaction catalyzed by the enzyme GTP cyclohydrolase I. The activity of GTP cyclohydrolase I is induced by interferon-γ (IFN-γ) a cytokine produced by T-lymphocytes and natural killer cells. The pro-inflammatory cytokines, e.g. interleukin-1 or interleukin-6, are known to increase neopterin production. Therefore, systemic concentrations of neopterin reflect both systemic immune and inflammatory response (8) . Neopterin may be measured in serum or in urine, and both serum and urinary neopterin concentrations have been validated as indicators of systemic immune and inflammatory response in disorders ranging from cancer to viral infections, transplant rejection, or atherosclerosis (8) .
In clinical practice, the presence of active neoplastic disease is often assessed by measuring tumor markers in the serum. A number of tumor markers are routinely used in epithelial tumors. In melanoma, only few tumor markers are available. S-100-beta is a protein expressed by glial cells, dendritic cells and melanocytes as well as by melanoma cells. Serum concentrations of S-100-beta were demonstrated to be increased in patients with recurrent melanoma and higher concentrations were indicative of poor prognosis (9-11).
The literature on neopterin as a marker of systemic immune activation in patients with malignant melanoma is limited (12) (13) (14) . In the present study, we evaluated serum concentrations of neopterin and a tumor marker, S-100-beta, in patients with malignant melanoma.
Materials and Methods
Forty-one patients, 19 females and 22 males, aged 60 ± 13 (range 31 -86) years with histologically verified malignant melanoma were included in the study. Two patients had uveal melanoma and remaining 39 patients had skin primary. Five patients had recurrent/metastatic disease and 36 patients were without disease recurrence. Two patients with no evidence of recurrence were under therapy with interferon-alpha. In all patients, neopterin determination was performed in serum samples obtained for biochemical examination during routine care after the patient consent was obtained. The samples were stored at −20°C until analysis. Neopterin was determined with radioimmunoassay using a commercial kit (BRAHMS, Hennigsdorf, Germany) according to the instructions of the manufacturer. Serum S-100-beta was determined by an immunoassay on Elecsys 2010 analyzer using commercial kit (Roche Diagnostics, Basel, Switzerland) according to the instructions of the manufacturer. Twenty healthy subjects, 15 females and 5 males, aged 43 ± 12 (range 25 -61) years, served as controls.
Differences between groups of patients or controls were analyzed by the Mann-Whitney U test. Correlations were analyzed using Spearman's rank correlation coefficient. The decision on statistical significance was based on p = 0.05 level. The analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
Neopterin in the whole group of patients with melanoma was not significantly different compared to controls (5.4 ± 3.9, range 2.1 -18.4 vs. 4.6 ± 0.8, range 3.5 -6.8 nmol/L). In melanoma patients, mean serum concentration of S-100-beta was 0.134 ± 0.328 (range 0.015 -1.750 µg/L). In 5 patients with recurrent/metastatic disease both neopterin (10.4 ± 4.9, range 5.1 -18.4 nmol/L) and S-100-beta (0.744 ± 0.735, range 0.036 -1.750 µg/L) were significantly increased compared to 36 patients with no evidence of recurrence (neopterin: 4.7 ± 3.3, range 2.1 -18.3 nmol/L, p < 0.01; S-100-beta: 0.050 ± 0.032, range 0.015 -0.172 µg/L, p <0.01). Serum neopterin in patients with recurrent disease was also significantly increased compared to controls (p <0.01). When two patients with recurrence who were under interferon-alpha therapy were excluded, the difference between patients with or without recurrence was even more pronounced. Among patients without recurrence, serum neopterin in patients with history of other malignancy was similar to patients without history of malignancy (4.3 ± 0.9, range 3.8 -5.6 vs. 4.0 ± 1.6, range 2.1 -8.2 nmol/L). A significant correlation was also observed between serum neopterin and S-100-beta (r s = 0.33, p <0.05). A significant correlation between age and neopterin concentrations was also observed in patients without evidence of disease activity (r s = 0.51, p = 0.002). 
Discussion
Present data demonstrate an increase of serum neopterin concentrations in patients with malignant melanoma that is limited to patients with active disease. An increase in serum or urinary neopterin concentrations in cancer patients has been amply documented (15, 16) , but less is known about neopterin in patients with melanoma. Neopterin determination has been used to monitor systemic effects of cytokine therapy in melanoma patients. Neopterin concentrations increased significantly after the administration of interferon-alpha or interleukin-2 alone or in combination with chemotherapy (17) (18) (19) (20) . In some of these studies, the increase in neopterin concentrations was accompanied by decreased tryptophan or increased kynurenine that reflect the activity of another IFN-γ-induced enzyme, indoleamine (2,3)-dioxygenase (17) (18) (19) . Other studies have focused on comparing neopterin in patients with early or advanced melanoma. Zitko et al. (12) observed increased urinary neopterin in 17 patients with malignant melanoma, specifically in patients with evidence of disease activity. Mura et al. (13) studied urinary neopterin during follow-up of 151 patients with cutaneous melanoma after primary surgery. Urinary neopterin in patients without recurrence was within the normal range, but increased urinary neopterin levels were observed in patients with lymph node or visceral metastases. Weinlich et al. (14) also observed increased serum neopterin concentrations in patients with melanoma that correlated strongly with tryptophan/kynurenine ratio.
Neopterin is increased in different disorders associated with systemic immune or inflammatory response, therefore determination of neopterin would be of little use in diagnosis. Increased neopterin concentrations are thought to reflect immune dysregulation. In patients with tumors of different primary locations, increased serum or urinary neopterin concentrations were associated with poor prognosis (15, 16) . The number of patients in the present study and short follow up did not allow us to investigate the prognostic significance of serum neopterin concentrations. However, present data indicate that measurement of neopterin could be helpful in the detection of recurrence. A significant correlation was also observed with the melanoma marker S-100-beta. It remains to be determined in future studies whether the combined measurement of serum neopterin and S-100-beta could be useful in the detection of recurrence in patients with melanoma.
In conclusion, serum neopterin is increased in patients with active melanoma. Serum neopterin correlates with age and the concentrations of melanoma marker S-100-beta.
